Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Efkarpia – page 22

680 clinical trials in Efkarpia, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Efkarpia at a glance
680
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

680 trials in Efkarpia

Open in trial search

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemastine Fumarate
  • Sponsor:Rheacell GmbH & Co. KG

Pulmonary arterial hypertension

Not yet recruiting

Efficacy and Safety of Sodium Valproate Added to Standard Therapy in Patients with Stable Pulmonary Arterial Hypertension – Phase 2b Randomized Study

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Valproate
  • Sponsor:Cereno Scientific AB

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiac failure acute+1

Not yet recruiting

Efficacy of istaroxime versus placebo (sodium chloride) infusion in patients with cardiogenic shock due to acute heart failure

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Istaroxime
  • Sponsor:Seismic Pharmaceuticals Operations LLC

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Efkarpia

What the registry says about research in the country

01 Dermatology Research

Extensive trials focusing on hidradenitis suppurativa and atopic dermatitis, evaluating novel therapeutic approaches and treatment combinations to improve patient outcomes.

  • Chronic skin conditions
  • Inflammatory disorders
  • Autoimmune skin diseases

Multiple studies testing new biological therapies and their long-term safety profiles.

02 Autoimmune Conditions

Research centered on lupus erythematosus and Sjögren's Disease, investigating targeted therapies to manage disease progression and symptoms.

  • Systemic autoimmune diseases
  • Novel immunological treatments
  • Disease activity markers

Studies aim to evaluate new therapeutic agents for better disease control.

03 Metabolic Disorders

Innovative trials examining treatments for Type 2 Diabetes and obesity, with focus on cardiovascular outcomes and weight management.

  • Diabetes management
  • Weight control therapies
  • Cardiovascular risk reduction

Research comparing new therapeutic options against established treatments.

04 Oncology Studies

Advanced research in metastatic breast cancer and colorectal cancer, evaluating targeted therapies and combination treatments.

  • HER2-positive cancers
  • Treatment resistance
  • Combination therapies

Focus on improving progression-free survival in advanced disease stages.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.